Transiently elevated D-dimer levels post-concentrated ascites reinfusion therapy cannot be used to predict deep vein thrombosis-pulmonary embolism

J Obstet Gynaecol Res. 2022 Mar;48(3):817-823. doi: 10.1111/jog.15162. Epub 2022 Jan 24.

Abstract

Aim: Cell-free and concentrated ascites reinfusion therapy (CART) is useful for treating malignant ascites. We have previously experienced cases with no DVT-PE despite a marked elevation in D-dimer post-CART. In this study, we assessed the changes in the D-dimer levels in patients who received CART and investigated the association between elevated D-dimer levels and occurrence of DVT-PE.

Methods: We performed an observational retrospective analysis of patients with gynecological malignancies treated with CART between March 2018 and April 2021. The selected patients had their D-dimer levels measured before and post-CART. The presence or absence of clinical DVT-PE findings was then examined, and contrast-enhanced computed tomography was performed using a DVT protocol in some cases.

Results: Eleven patients received 17 CART procedures in this study. Patients of 16 procedures (94.1%) showed a significant elevation in D-dimer levels on day 1 post-CART. Changes in D-dimer levels were monitored in these patients of 16 procedures. In all 16 cases, the D-dimer levels decreased after day 2 post-CART. Only one patient, who presented with respiratory failure, out of the patients of 16 procedures (6.2%) with elevated D-dimer levels on day 1 had PE.

Conclusions: D-dimer elevation after CART is likely to be transient and a false-positive. None of the patients in this study had PE if they were asymptomatic after CART, there is no need to strongly suspect PE only by D-dimer elevation. In conclusion, D-dimer measurement immediately post-CART is not helpful in predicting the diagnosis of DVT-PE.

Keywords: D-dimer; ascites; concentrated ascites reinfusion therapy; deep vein thrombosis-pulmonary embolism; ovarian cancer.

MeSH terms

  • Ascites / diagnosis
  • Ascites / therapy
  • Fibrin Fibrinogen Degradation Products
  • Humans
  • Pulmonary Embolism* / diagnosis
  • Retrospective Studies
  • Venous Thrombosis* / diagnosis
  • Venous Thrombosis* / therapy

Substances

  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D